ArticleJournal of molecular histology2026
Prophylactic administration of silica nanoparticles loaded with amifostine prevents cisplatin-induced nephrotoxicity in rats.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced nephrotoxicity is a major limitation in chemotherapy, particularly with cisplatin, necessitating effective renal-protective strategies. Amifostine, a thiol-based prophylactic agent, has potential to mitigate such toxicity. This study demonstrates a prophylactic nephroprotective strategy where SiNPs@AMF was administered prior to and during cisplatin treatment and development of novel nano-emulsified formulation to potentially overcome the limitations of free amifostine, such as its short half-life and systemic side effects. Hollow silica nanoparticles loaded with amifostine were prepared via ultrasonication and characterized by transmission electron microscopy (TEM), dynamic light scattering (DLS), and zeta potential analysis. Fifty male Wistar rats were randomly assigned to five groups: normal control, nano-emulsion control (SiNPs), nephrotoxic (cisplatin), amifostine nano-emulsion (SiNPs@AMF), and combined treatment (SiNPs@AMF + cisplatin). Cisplatin-induced nephrotoxicity was established by intraperitoneal injections (20 mg/kg, twice day after day). Serum inflammatory and extracellular matrix biomarkers (HA, MMP-9, NF-κB, MCP-1) were quantified by ELISA.urea, creatinine by spectrophotometer. Renal microRNA (miR-29a, miR-193a) and podocyte markers (podocin, nephrin) were evaluated using quantitative real-time PCR. P53 expression was assessed via immunohistochemistry. Cisplatin markedly increased serum urea, creatinine, HA, MMP-9, NF-κB, and MCP-1, downregulated miR-29a, podocin, and nephrin, and upregulated miR-193a, accompanied by elevated P53 immunoreactivity. Treatment with SiNPs@AMF significantly attenuated inflammatory and extracellular matrix disruptions, restored miR-29a, podocin, and nephrin expression, reduced miR-193a overexpression, and decreased P53 staining. Silica nano-emulsified amifostine effectively mitigates cisplatin-induced nephrotoxicity by suppressing inflammation, preserving extracellular matrix integrity, and restoring renal microRNA balance. These findings support the therapeutic potential of nano-formulated thiol compounds as a targeted strategy to prevent chemotherapy-associated renal injury.
Indexed as
Identifiers
42530708What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.